Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estramustine, Docetaxel, and Carboplatin in HRPC
NCT00183924Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Mar 2001
- Primary completion
- Jul 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of estramustine, docetaxel and carboplatin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Southern California. Started Mar 2001; status: completed.
02
Drugs
estramustinedocetaxelcarboplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00183924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183924.